Peer-Reviewed Published Study Demonstrates Safety of UC-II

A newly published study demonstrates that UC-II®, InterHealth Nutraceuticals’ 40 mg, once-a-day, joint-health ingredient, is safe. The new study was published in Toxicology Mechanisms and Methods and adds to the growing body of evidence supporting UC-II’s use in joint-health supplements and functional food and beverages. UC-II has also been determined GRAS (Generally Recognized as Safe) and is backed by published broad spectrum safety and clinical research demonstrating its benefits in increasing joint health.

A battery of toxicological studies were performed and analyzed by Eurofins Product Safety Laboratories, a GLP approved lab, in conjunction with researchers from InterHealthResearchCenter, University of Houston College of Pharmacy and Murray State University Toxicology Department. The researchers conducted a 90-day sub-chronic toxicity study in male and female Sprague Dawley rats as well as acute oral, acute dermal, primary dermal irritation, primary eye irritation toxicity studies, Ames' bacterial reverse mutation assay and mouse lymphoma tests to determine the safety of UC-II. In the 90-day study, amounts of UC-II equivalent to up to 100x the human recommended dose were shown to be safe with no adverse events reported. Results of the acute toxicity studies demonstrated an oral LD50 of >5000 mg/kg and the acute dermal LD50 of >2000 mg/kg. UC-II was determined to be non-mutagenic in Ames’ bacterial reverse mutation assays and in cell gene mutation assays.

This new study is consistent with safety findings in humans, dogs and horses, which have shown UC-II to be well tolerated with no serious adverse side effects. “Results from the current study combined with animal and human data demonstrate the broad-spectrum safety of UC-II,” wrote the researchers. Commenting on the study data, Paul Dijkstra, InterHealth’s CEO said, “These findings validate the safety and clinical value of UC-II. We believe that UC-II offers manufacturers an opportunity to provide consumers with safe and effective joint-health support. With the continued increase in the older population, joint-health problems are becoming a major medical and financial concern. UC-II offers a cost-effective way to support joint mobility, flexibility and comfort, which – in these tough economic times – is a big win for consumers.”

About InterHealth Nutraceuticals, Inc.

InterHealth Nutraceuticals researches, develops, markets and distributes specialty nutritional ingredients, which are sold worldwide to manufacturers of dietary supplements and nutraceutical food and beverage products. The company’s products include UC-II®, an all-natural ingredient for joint health; Super CitriMax®, a weight management and satiety ingredient; and ChromeMate®, a niacin-bound chromium product that addresses both blood sugar and cardiovascular health. In addition, InterHealth offers Aller-7®, OptiBerry®, L-OptiZinc®, Protykin® and ZMA®. For more information about InterHealth and its products, call 1-800-783-4636 or 1-707-751-2800 (outside U.S.) or visit the website at

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.